Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2024 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

23andme holding co - ME

ME

Close Chg Chg %
3.61 -0.16 -4.44%

Open Market

3.45

-0.16 (4.44%)

Volume: 203.26K

Last Updated:

Dec 3, 2024, 12:25 PM EDT

Trade Now

Company Overview: 23andme holding co - ME

ME Key Data

Open

$3.58

 Day Range

3.43 - 3.87

52 Week Range

2.66 - 20.40

 Market Cap

$669.49M

Shares Outstanding

185.46M

 Public Float

16.02M

Beta

1.16

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$25.27

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

493.82K

  

ME Performance

1 Week
 
 1.55%
 
1 Month
 
 -22.47%
 
3 Months
 
 -42.76%
 
1 Year
 
 -79.80%
 
5 Years
 
 N/A
 

ME Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 1
Full Ratings ➔

About 23andme holding co - ME

23andMe Holding Co. is a consumer genetics and research company, which engages in assisting people to access, understand, and benefit from the human genome. It operates through the Consumer and Research Services, and Therapeutics segments. The Consumer and Research Services segment consists of Personal Genome Service, Telehealth Business, and Research Services. The Therapeutics segment focuses on the genetic insights of genetic and phenotypic information. The company was founded by Anne E. Wojcickiin 2006 and is headquartered in Sunnyvale, CA.

ME At a Glance

23andMe Holding Co.
223 North Mathilda Avenue
Sunnyvale, California 94086
Phone 1-650-938-6300 Revenue 219.64M
Industry Biotechnology Net Income -666,704,000.00
Sector Health Technology Employees 582
Fiscal Year-end 03 / 2025
View SEC Filings

ME Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 1.153
Price to Book Ratio 1.383
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -0.386
Enterprise Value to Sales 0.509
Total Debt to Enterprise Value 0.684

ME Efficiency

Revenue/Employee 377,384.88
Income Per Employee -1,145,539.519
Receivables Turnover 24.203
Total Asset Turnover 0.328

ME Liquidity

Current Ratio 1.967
Quick Ratio 1.87
Cash Ratio 1.711

ME Profitability

Gross Margin 31.823
Operating Margin -145.23
Pretax Margin -303.514
Net Margin -303.547
Return on Assets -99.674
Return on Equity -147.753
Return on Total Capital -251.553
Return on Invested Capital -127.225

ME Capital Structure

Total Debt to Total Equity 40.587
Total Debt to Total Capital 28.87
Total Debt to Total Assets 19.363
Long-Term Debt to Equity 35.988
Long-Term Debt to Total Capital 25.599
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for 23andme Holding Co - ME

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
243.92M 271.89M 299.49M 219.64M
Sales Growth
-20.15% +11.47% +10.15% -26.66%
Cost of Goods Sold (COGS) incl D&A
147.16M 165.10M 201.49M 149.74M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
20.25M 26.15M 36.50M 29.48M
Depreciation
18.08M 23.70M 14.80M 11.00M
Amortization of Intangibles
2.17M 2.45M 21.70M 18.48M
COGS Growth
-22.66% +12.19% +22.04% -25.68%
Gross Income
96.76M 106.80M 98.00M 69.89M
Gross Income Growth
-15.99% +10.37% -8.24% -28.68%
Gross Profit Margin
+39.67% +39.28% +32.72% +31.82%
2021 2022 2023 2024 5-year trend
SG&A Expense
281.96M 351.55M 422.01M 388.88M
Research & Development
147.16M 181.16M 215.88M 199.34M
Other SG&A
134.80M 170.39M 206.13M 189.53M
SGA Growth
-14.28% +24.68% +20.04% -7.85%
Other Operating Expense
- - - -
-
Unusual Expense
- - (23.59M) 360.11M
-
EBIT after Unusual Expense
(185.20M) (221.16M) (324.01M) (679.09M)
Non Operating Income/Expense
1.58M 194.00K 9.58M 12.46M
Non-Operating Interest Income
- 277.00K 9.68M 14.33M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - -
-
Interest Expense Growth
- - - -
-
Gross Interest Expense
- - - -
-
Interest Capitalized
- - - -
-
Pretax Income
(183.62M) (220.97M) (314.43M) (666.63M)
Pretax Income Growth
+26.81% -20.34% -42.29% -112.01%
Pretax Margin
-75.28% -81.27% -104.99% -303.51%
Income Tax
- (3.48M) (2.77M) 73.00K
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(183.62M) (217.49M) (311.66M) (666.70M)
Minority Interest Expense
- - - -
-
Net Income
(183.62M) (217.49M) (311.66M) (666.70M)
Net Income Growth
+26.81% -18.45% -43.30% -113.92%
Net Margin Growth
-75.28% -79.99% -104.06% -303.55%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(183.62M) (217.49M) (311.66M) (666.70M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(183.62M) (217.49M) (311.66M) (666.70M)
EPS (Basic)
-9.0356 -0.6016 -0.6903 -28.0138
EPS (Basic) Growth
+26.81% +93.34% -14.74% -3,958.21%
Basic Shares Outstanding
20.32M 361.53M 451.50M 23.80M
EPS (Diluted)
-9.0356 -0.6016 -0.6903 -28.0138
EPS (Diluted) Growth
+26.81% +93.34% -14.74% -3,958.21%
Diluted Shares Outstanding
20.32M 361.53M 451.50M 23.80M
EBITDA
(164.95M) (218.60M) (287.51M) (289.50M)
EBITDA Growth
+13.87% -32.53% -31.52% -0.69%
EBITDA Margin
-67.62% -80.40% -96.00% -131.81%

Snapshot

Average Recommendation BUY Average Target Price 8.40
Number of Ratings 1 Current Quarters Estimate N/A
FY Report Date N/A Current Year's Estimate N/A
Last Quarter’s Earnings -2.32 Median PE on CY Estimate N/A
Year Ago Earnings -28.00 Next Fiscal Year Estimate N/A
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates N/A N/A N/A N/A
Mean Estimate N/A N/A N/A N/A
High Estimates N/A N/A N/A N/A
Low Estimate N/A N/A N/A N/A
Coefficient of Variance N/A N/A N/A N/A

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 1 1 1
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for 23andme Holding Co - ME

Date Name Shares Transaction Value
Jul 3, 2024 Peter J. Taylor Director 322,732 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 3, 2024 Sandra Rae Hernández Director 395,064 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 3, 2024 Valerie C. Montgomery Rice Director 354,881 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 24, 2024 Joseph Selsavage Chief Financial & Actng Ofcr 2,258,390 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 22, 2024 Kathy L. Hibbs Chief Administrative Officer 1,217,033 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $0.55 per share 669,368.15
May 22, 2024 William Richards Head of Therapeutics Discovery 630,434 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $0.55 per share 346,738.70
May 7, 2024 Kathy L. Hibbs Chief Administrative Officer 1,252,315 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $0.49 per share 613,634.35
May 7, 2024 Kathy L. Hibbs Chief Administrative Officer N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00

23andme Holding Co in the News

Markets

23andMe cuts 40% of its workforce

Genetics testing company 23andMe is trimming its headcount by 40%. The company said it is undergoing a restructuring to "streamline operations and reduce costs."